Executive Committee

Medicure is committed to maintaining the highest level of integrity and ethical responsibility. We believe that these values start with strong leadership. Our management team is led by a multidisciplinary group of highly educated leaders that have significant experience in pharmaceutical product development and commercialization.

Albert D. Friesen, PhD.

Chief Executive Officer & Chairman of the Board

Albert D. Friesen is a founder and has served as CEO and Chair of Medicure Inc. since 1997. He is also a founder of Genesys Venture Inc. (GVI), and current serves as President. Dr. Friesen has been instrumental in the founding and development of several health industry companies, including ABI Biotechnology (now Apotex Fermentation), Canada's first profitable biotech company, and the Winnipeg Rh Institute, where he led the development of Canada's first biotech product, WinRho. Dr. Friesen has also played a key role in a number of regional and national organizations, including a founder and first Board of Director Chair of the Industrial Biotechnology Association of Canada (now BIOTECanada). Dr. Friesen received his Ph.D. in protein chemistry from the University of Manitoba.

Neil Owens, PhD.

President & Chief Operating Officer

Neil Owens, Ph.D. has worked with Medicure since 2014, serving in various positions of escalating responsibility within Medical Affairs, and most recently as Director, Scientific Affairs. Dr. Owens is currently responsible for implementing Medicure's strategic plans and overseeing day-to-day operations including the advancement and management of new and existing pharmaceutical products. Dr. Owens received his Ph.D. in Chemistry from the University of Manitoba and has Postdoctoral experience with the European Institute of Chemistry and Biology (Bordeaux, France). His research background has focused on organic & medicinal chemistry, and overall the application of science towards solving health-related issues.

Reuben Saba, PhD.

Vice President, Scientific and Medical Affairs

Reuben Saba, Ph.D. was appointed Vice President of Scientific and Medical Affairs in July 2019 and is responsible for clinical development and medical activities at Medicure Inc. Dr. Saba began his tenure at Medicure as a Medical Science Liaison in the U.S. Midwest Regions and was appointed Regional Medical Affairs Manager in 2015 for the US Midwest and Northeast regions. Dr. Saba was appointed to Director of Medical Affairs, Medical Information and Medical-Technical Marketing in 2019. Dr. Saba joined Medicure from the Public Health Agency of Canada (PHAC) in the Molecular Pathobiology Department focusing on the host genetics involved in prion pathobiology. Dr. Saba obtained his M.Sc. and Ph.D. at the University of Manitoba and did further post-doctoral training at the Interdisciplinary Center for Neurosciences (IZN) at the University of Heidelberg (Heidelberg, Germany).

David Gurvey, CPA, CMA, B.Sc.

Chief Financial Officer

David Gurvey is an accomplished finance leader with an established track record of strong financial stewardship and strategically building company value. He previously held the position of Chief Financial Officer for DiaMedica Therapeutics, where he was involved in key strategic transactions contributing to growth in company value from $2.4 million to $40 million. He has the capabilities and qualifications to accelerate Medicure's growth and business strategy.

Unite Interactive